Some of the clinical advantages of Idrapainux include: (1) A linear pharmacokinetic profile and a longer half-life than Fondaparinux; (2) It has consistent effects as it is not metabolized and is completely bioavailable; (3) It does not bind to plasma proteins and in particular does not bind platelet factor 4 (PF4), which makes the development of immune thrombocytopenia extremely unlikely [36]. This evidence concerns the gene PF4 and autoimmune thrombocytopenic purpura.